Renalytix (LSE:RENX) has signed a multi-year agreement with Quest Diagnostics to expand access to its kidneyintelX.dkd blood test across the United States.

Under the agreement, physicians in the U.S. will be able to order kidneyintelX.dkd through Quest’s connectivity and specimen collection network. Renalytix will perform the assay at its laboratory in New York and will remain responsible for billing for the test.

Availability through the Quest network is targeted for early 2027.

Agreement includes potential in-licensing option

The arrangement also gives Quest an option to in-license kidneyintelX.dkd after specified commercialisation milestones have been achieved.

The supplied information does not specify the financial terms of the multi-year agreement or the commercialisation milestones associated with the licensing option.

Renalytix said the partnership is intended to expand physician access to kidneyintelX.dkd by using Quest’s U.S. connectivity and collection infrastructure.

KidneyintelX.dkd targets diabetic kidney disease

KidneyintelX.dkd is a blood-based test developed to assess the risk of progressive kidney function decline in adults with type 2 diabetes and early-stage chronic kidney disease.

The test has received U.S. Food and Drug Administration authorisation and Medicare reimbursement.

Renalytix is an AI-enabled in vitro diagnostics company focused on precision medicine for kidney disease. Its KidneyIntelX technology uses data-driven analysis to assess the risk of progressive kidney function decline in patients with early-stage diabetic kidney disease.